FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy

1University of Missouri-Kansas City School of Medicine.
AJP Endocrinology and Metabolism (Impact Factor: 3.79). 02/2013; 304(8). DOI: 10.1152/ajpendo.00596.2012
Source: PubMed


Fibroblast growth factor 23 (FGF23) is a hormone primarily released by osteocytes that regulates phosphate and vitamin D metabolism. Recent observational studies in humans suggest that circulating FGF23 is independently associated with cardiac hypertrophy and increased mortality, but it is unknown if FGF23 can directly alter cardiac function. We found that FGF23 significantly increased cardiomyocyte cell size in vitro, the expression of gene markers of cardiac hypertrophy, and total protein content of cardiac muscle. In addition, FGFR1 and FGFR3 mRNA were the most abundantly expressed FGF receptors in cardiomyocytes and the co-receptor α-Klotho was expressed at very low levels. We tested an animal model of chronic kidney disease (Col4a3(-/-) mice) which has elevated serum FGF23. We found elevations in common hypertrophy gene markers in Col4a3(-/-) hearts compared to wild type, but did not observe changes in wall thickness or cell size by week 10. However, the Col4a3(-/-) hearts did show reduced fractional shortening (-17%) and ejection fraction (-11%). Acute exposure of primary cardiomyocytes to FGF23 resulted in elevated intracellular Ca(2+) ([Ca2+]i) (F/Fo +86%) which was blocked by verapamil pretreatment. FGF23 also increased ventricular muscle strip cardiac contractility (67%) which was inhibited by FGF receptor antagonism. We hypothesize that while FGF23 can acutely increase [Ca(2+)]i , chronically this may lead to decreases in contractile function or stimulate cardiac hypertrophy as observed with other stress hormones. In conclusion, FGF23 is a novel bone-heart endocrine factor and may be an important mediator of cardiac Ca2+ regulation and contractile function during chronic kidney disease.

Download full-text


Available from: Michael J Wacker,
150 Reads
  • Source
    • "FGF23 activated calcineurin/NFAT signaling in cultured cardiomyocytes. These findings indicate that FGF23 promotes cardiac hypertrophy by activating calcineurin/NFAT signaling in an endocrine manner (Table 1) (Faul et al., 2011; Faul, 2012; Touchberry et al., 2013). However, the mechanism of αKlotho-independent FGF23 signaling remains unclear. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac remodeling progresses to heart failure, which represents a major cause of morbidity and mortality. Cardiomyokines, cardiac secreted proteins, may play roles in cardiac remodeling. Fibroblast growth factors (FGFs) are secreted proteins with diverse functions, mainly in development and metabolism. However, some FGFs play pathophysiological roles in cardiac remodeling as cardiomyokines. FGF2 promotes cardiac hypertrophy and fibrosis by activating MAPK signaling through the activation of FGF receptor (FGFR) 1c. In contrast, FGF16 may prevent these by competing with FGF2 for the binding site of FGFR1c. FGF21 prevents cardiac hypertrophy by activating MAPK signaling through the activation of FGFR1c with β-Klotho as a co-receptor. In contrast, FGF23 induces cardiac hypertrophy by activating calcineurin/NFAT signaling without αKlotho. These FGFs play crucial roles in cardiac remodeling via distinct action mechanisms. These findings provide new insights into the pathophysiological roles of FGFs in the heart and may provide potential therapeutic strategies for heart failure.
    Frontiers in Physiology 09/2013; 4:247. DOI:10.3389/fphys.2013.00247 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The fibroblast growth factor receptors (FGFR) play a major role in angiogenesis and are desirable targets for the development of therapeutics. Groups of Wistar-Han rats were dosed orally once daily for 4 days with a small molecule pan-FGFR inhibitor (5mg/kg) or once daily for 6 days with a small molecule MEK inhibitor (3mg/kg). Serum phosphorous and FGF23 levels increased in all rats during the course of the study. Histologically, rats dosed with either drug exhibited multifocal, multi-organ soft tissue mineralization. Expression of the sodium phosphate transporter Npt2a and the vitamin D metabolizing enzymes Cyp24a1 and Cyp27b1 were modulated in kidneys of animals dosed with the pan-FGFR inhibitor. Both inhibitors decreased ERK phosphorylation in the kidneys and inhibited FGF23-induced ERK phosphorylation in vitro in a dose-dependent manner. A separate cardiovascular outcome study was performed to monitor hemodynamics and cardiac structure and function of telemetered rats dosed with either the pan-FGFR inhibitor or MEK inhibitor for three days. Both compounds increased blood pressure (~+17 mmHg), decreased heart rate (~-75bpm), and modulated echocardiography parameters. Our data suggest that inhibition of FGFR signaling following administration of either pan-FGFR inhibitor or MEK inhibitor interferes with the FGF23 pathway, predisposing animals to hyperphosphatemia and a tumoral calcinosis-like syndrome in rodents.
    Toxicological Sciences 07/2013; 135(2). DOI:10.1093/toxsci/kft161 · 3.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Left ventricular hypertrophy (LVH), a common complication in chronic kidney disease (CKD), is associated with high cardiovascular mortality. The aim of this experimental study was to analyze the effect of different vitamin D receptor activators (VDRAs) on both LVH and myocardial fibrosis in chronic renal failure (CRF). Male Wistar rats with CRF, carried out by 7/8 nephrectomy, were treated intraperitoneally with equivalent doses of VDRAs (calcitriol, paricalcitol and alfacalcidol, 5 days per week) during 4 weeks. A placebo group (CRF + vehicle) and a Sham group with normal renal function served as controls. Biochemical, morphological, functional and molecular parameters associated with LVH were evaluated, as well as cardiac fibrosis, collagen I, transforming growth factor β1 (TGFβ1) and matrix metalloproteinase-1 (MMP1) expression. All VDRAs treatment prevented LVH, with values of cardiomyocyte size, LV wall and septum thickness and heart-body weight ratio similar to those observed in the Sham group. At molecular levels, all VDRAs attenuated atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) expression compared with CRF + vehicle. The phosphorylation of ERK1/2, a signal for activating growth, was stimulated in the CRF + vehicle group; VDRAs use prevented this activation. Paricalcitol was the only VDRA used that maintained in the normal range all parameters associated with myocardial fibrosis (total collagen, collagen I, TGFβ1 and MMP1). Our findings demonstrated that the three VDRAs used induced similar changes in bone metabolic parameters and LVH. In addition, paricalcitol was the only VDRA which showed a relevant beneficial effect in the reduction of myocardial fibrosis, a key factor in the myocardial dysfunction in CKD patients.
    Nephrology Dialysis Transplantation 09/2013; 28(11). DOI:10.1093/ndt/gft268 · 3.58 Impact Factor
Show more